Table 1.

Inclusion and exclusion criteria

Inclusion criteria	Definition
PCI 30–90 days before study inclusion	Elective or emergency procedure
Dual/triple antithrombotic therapy	Including a P2Y12 inhibitor
Classified as ‘vulnerable’ by ≥ 3 predefined risk factors:	Age ≥ 75 years
	Female gender
	Renal dysfunction (MDRD-eGFR ≤ 60 ml/min)
	Body weight ≤ 60 kg
	Hypertension (previously diagnosed, or on medication)
	Diabetes mellitus
	Anaemia (Hb < 8.2 mmol/l for men, < 7.3 mmol/l for women)
	Previous stroke
	Previous major bleeding
	Liver dysfunction (known hepatitis or transplant)
	History of gastric/duodenal ulcers
	Daily use of NSAIDs or SSRIs
	Triple antithrombotic therapy (DAPT + oral anticoagulants)
	Previous in-stent thrombosis or high risk coronary stent (≥ 3 lesions treated, total stent length > 60 mm, last remaining vessel, or left main coronary artery stenting)
Exclusion criteria	Definition
Known platelet function disorders	Previously diagnosed platelet function disorders
Recent coronary intervention	PCI or CABG ≤ 7 days
Recent new ischaemic event	ACS or stroke ≤ 7 days
Signs of active infection	Fever, antibiotic treatment or hospital admission during laboratory assessment of platelet function
Medication non-compliance	Confirmed non-compliance in antithrombotic medication by patient interview or pharmacy dispensing

PCI percutaneous coronary intervention, MDRD-eGFR Modification of Diet in Renal Disease—estimated glomerular filtration rate, Hb Haemoglobin, NSAIDs non-steroidal anti-inflammatory drugs, SSRIs selective serotonin reuptake inhibitors, DAPT dual antiplatelet therapy, CABG coronary artery bypass graft, ACS acute coronary syndrome